S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:ORTX

Orchard Therapeutics (ORTX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$16.70
$16.70
50-Day Range
$16.40
$16.70
52-Week Range
$4.24
$16.72
Volume
N/A
Average Volume
157,287 shs
Market Capitalization
$380.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00

Orchard Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
49.7% Upside
$25.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.01mentions of Orchard Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.25) to ($4.85) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.48 out of 5 stars

Medical Sector

889th out of 938 stocks

Biotechnology Industry

27th out of 30 stocks

ORTX stock logo

About Orchard Therapeutics Stock (NASDAQ:ORTX)

Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company's program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations. In addition, it develops program for immunological disorders consist of pre-clinical programs, which includes OTL-104 for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2; and OTL-105 for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom. As of January 24, 2024, Orchard Therapeutics plc operates as a subsidiary of Kyowa Kirin Co., Ltd..

ORTX Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
See More Headlines
Receive ORTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orchard Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/15/2023
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ORTX
Fax
N/A
Employees
166
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$25.00
High Stock Price Target
$34.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+49.7%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-150,660,000.00
Net Margins
-333.90%
Pretax Margin
-334.54%

Debt

Sales & Book Value

Annual Sales
$22.66 million
Book Value
$7.74 per share

Miscellaneous

Free Float
22,099,000
Market Cap
$380.09 million
Optionable
Optionable
Beta
0.55
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Hubert Baburaj Gaspar M.D. (Age 61)
    Ph.D., CEO, Member of Scientific Advisory Board & Executive Director
    Comp: $901.42k
  • Mr. Frank Edward Thomas (Age 55)
    President & COO
    Comp: $763.95k
  • Dr. Nicoletta Loggia Ph.D.
    R.Ph., Chief Technical Officer
  • Dr. Fulvio Mavilio Ph.D.
    Chief Scientific Officer
  • Ms. Renee T. Leck
    Head of Investor Relations
  • Benjamin Navon
    Director of Corporate Communications
  • Mr. John Cerio
    Chief Human Resource Officer
  • Mr. Robin Kenselaar
    Senior VP & GM of EMEA Commercial Operations
  • Mr. Braden Parker
    Chief Commercial Officer
  • Dr. Leslie Meltzer Ph.D.
    Chief Medical Officer

ORTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Orchard Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ORTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ORTX, but not buy additional shares or sell existing shares.
View ORTX analyst ratings
or view top-rated stocks.

What is Orchard Therapeutics' stock price target for 2024?

3 Wall Street analysts have issued 12 month price objectives for Orchard Therapeutics' shares. Their ORTX share price targets range from $16.00 to $34.00. On average, they expect the company's share price to reach $25.00 in the next twelve months. This suggests a possible upside of 49.7% from the stock's current price.
View analysts price targets for ORTX
or view top-rated stocks among Wall Street analysts.

How were Orchard Therapeutics' earnings last quarter?

Orchard Therapeutics plc (NASDAQ:ORTX) posted its earnings results on Monday, May, 15th. The company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($1.61) by $1.49. The business earned $1.24 million during the quarter, compared to analysts' expectations of $6.48 million. Orchard Therapeutics had a negative trailing twelve-month return on equity of 74.94% and a negative net margin of 333.90%.

When did Orchard Therapeutics' stock split?

Shares of Orchard Therapeutics reverse split before market open on Friday, March 10th 2023. The 1-10 reverse split was announced on Friday, March 10th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Orchard Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Orchard Therapeutics investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), Entasis Therapeutics (ETTX), Selecta Biosciences (SELB) and VBI Vaccines (VBIV).

When did Orchard Therapeutics IPO?

Orchard Therapeutics (ORTX) raised $200 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Orchard Therapeutics' major shareholders?

Orchard Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Blue Owl Capital Holdings LP (7.03%), Beryl Capital Management LLC (6.86%), Gabelli Funds LLC (0.99%), GABELLI & Co INVESTMENT ADVISERS INC. (0.85%), Goldman Sachs Group Inc. (0.60%) and Goldman Sachs Group Inc. (0.60%). Insiders that own company stock include Bobby Gaspar and Frank E Thomas.
View institutional ownership trends
.

This page (NASDAQ:ORTX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners